<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03643939</url>
  </required_header>
  <id_info>
    <org_study_id>RENOVATEmain_2018_08</org_study_id>
    <nct_id>NCT03643939</nct_id>
  </id_info>
  <brief_title>High-Flow Nasal Oxygen Cannula Compared to Non-Invasive Ventilation in Adult Patients With AcuTE Respiratory Failure</brief_title>
  <acronym>RENOVATE</acronym>
  <official_title>RandomizEd Adaptive Trial of High-Flow Nasal Oxygen Cannula Compared to Non-Invasive Ventilation for AcuTE Respiratory Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital do Coracao</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Berry Consultants</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital do Coracao</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RENOVATE study aims to investigate if the respiratory support device called High-Flow Nasal&#xD;
      Oxygen Cannula (HFNC) acts similarly (non-inferior) to another respiratory support device&#xD;
      called Non-Invasive positive-pressure Ventilation (NIPPV) in preventing endotracheal&#xD;
      intubation in adult patients with Acute Respiratory Failure (ARF) from different causes. HFNC&#xD;
      is a somewhat new method of respiratory support in adults that has been used in neonatal ARF&#xD;
      for some years. The reason this study is necessary is that, even though NIPPV has been&#xD;
      demonstrated to prevent endotracheal intubation (and its associated complications) in a broad&#xD;
      range of ARF patients, HFNC has been proposed to have the same beneficial effect of NIPPV&#xD;
      while being easier tolerated, allowing patients to talk, eat and drink through mouth while on&#xD;
      HFNC. RENOVATE will recruit between 800 to 2000 patients (adaptive design) with different&#xD;
      types of ARF in Brazil. Patients will be randomized to HFNC or NIPPV and the rate of&#xD;
      endotracheal intubation will be compared between groups as well as other parameters such as&#xD;
      vital status and other health care related complications.&#xD;
&#xD;
      [IMPORTANT NOTE] On April 13, 2021, on the first interim analysis, the DSMB recommended the&#xD;
      interruption of the immunocompromised hypoxemic ARF subgroup.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RENOVATE will investigate if High-Flow Nasal Oxygen Cannula (HFNC) is non-inferior to&#xD;
      Non-Invasive positive-pressure Ventilation (NIPPV) in preventing endotracheal intubation or&#xD;
      death in adult patients with Acute Respiratory Failure (ARF) from different causes in 7 days.&#xD;
      HFNC is a somewhat new method of respiratory support in adults that has been used in neonatal&#xD;
      ARF for some years. Even though NIPPV has been demonstrated to prevent endotracheal&#xD;
      intubation (and its associated complications) in a broad range of ARF patients, HFNC may have&#xD;
      beneficial effect over NIPPV because it is easier to be tolerated, allowing patients to talk,&#xD;
      eat and drink through mouth while on therapy. RENOVATE will recruit between 800 to 2000&#xD;
      patients (adaptive design) with different types of ARF in Brazil. The main hypothesis is that&#xD;
      HFNC is non inferior to NIPPV in reducing intubation rate or death within 7 days. However, as&#xD;
      an adaptive study, this non inferiority hypothesis may change to superiority if gathered data&#xD;
      during the study is promissing in the interim analysis. Therefore, sample size may increase&#xD;
      to 2000 participants. Patients will be randomized to HFNC or NIPPV and the rate of&#xD;
      endotracheal intubation will be compared between groups as well as other parameters such as&#xD;
      vital status and other health care related complications.&#xD;
&#xD;
      [IMPORTANT NOTE] On April 13, 2021, on the first interim analysis, the DSMB recommended the&#xD;
      interruption of the immunocompromised hypoxemic ARF subgroup.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Adaptive, non-inferiority randomized, open-label, controled clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endotracheal intubation rate or death</measure>
    <time_frame>in 7 days</time_frame>
    <description>proportion of endotracheal intubation or death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>in 28 days</time_frame>
    <description>Death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>in 90 days</time_frame>
    <description>Death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU free days</measure>
    <time_frame>in 28 days</time_frame>
    <description>Days out of ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IMV free days</measure>
    <time_frame>in 28 days</time_frame>
    <description>Days without IMV inside of ICU after 48 hours of being extubated</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>in 90 days</time_frame>
    <description>Time in hospital in days</description>
  </other_outcome>
  <other_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>in 90 days</time_frame>
    <description>Time in the ICU in days</description>
  </other_outcome>
  <other_outcome>
    <measure>Vasopressor free days</measure>
    <time_frame>in 28 days</time_frame>
    <description>Days without use of vasopressor inside of ICU</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients who received do-not-intubate-order</measure>
    <time_frame>in 7 days</time_frame>
    <description>Proportion of patients that received DNI order after randomization was done</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient confort score</measure>
    <time_frame>7 days</time_frame>
    <description>Visual scale varying from 0 (no disconfort) to 100 (maximal disconfort)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Respiratory Insufficiency</condition>
  <condition>Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>High Flow Nasal Catheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The HFNC (AIRVO2 Fisher &amp; Paykel, Auckland, New Zealand) consists of an apparatus that allows adjustable FiO2 from 21 to 100% and delivers flow up to 60 L/ min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-invasive positive pressure ventilation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NIPPV will be performed using the devices available on centers. Both a dedicated NIPPV device or invasive mechanical ventilator with NIPPV mode are accepted. The interface should be a oronasal or full face mask.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High Flow Nasal Catheter</intervention_name>
    <description>HFNC will deliver through AIRVO2. FiO2 from 21 to 100% and heated humidified gas flow up to 60 l / min with temperature of the circuit maintained at 37 degrees.&#xD;
Oxygen flow will be offered through a humidified nasal catheter. Flow and FiO2 will be titrated according to the protocol to maximize patient´s comfort and SpO2.</description>
    <arm_group_label>High Flow Nasal Catheter</arm_group_label>
    <other_name>Optiflow</other_name>
    <other_name>Airvo</other_name>
    <other_name>trans-nasal insufflation</other_name>
    <other_name>Nasal High Flow</other_name>
    <other_name>High Flow Nasal Cannula</other_name>
    <other_name>nasal cannula with high-flow oxygen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Noninvasive ventilation</intervention_name>
    <description>NIPPV will be performed using a facial mask (either oronasal or full face). NIPPV will deliver pressures and FiO2 tailored to specific ARF subgroups, according to the protocol. Adjustments of the inspiratory pressure (IPAP) and expiratory pressure (EPAP) and FiO2 according to protocol</description>
    <arm_group_label>Non-invasive positive pressure ventilation</arm_group_label>
    <other_name>BiPAP</other_name>
    <other_name>Non-invasive ventilation</other_name>
    <other_name>Noninvasive positive pressure ventilation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        [IMPORTANT NOTE] On April 13th 2021, in the first interim analysis, the DSMB recommended&#xD;
        for the interruption of the subgroup Immunocompromised De Novo Hypoxemic ARF due to&#xD;
        futility.&#xD;
&#xD;
        Sequential adult patients 18 years of age or older admitted to the ICU or emergency&#xD;
        department with acute onset respiratory distress suspected of having De Novo hypoxemic ARF&#xD;
        (non-immunocompromised) , Immunocompromised De Novo hypoxemic ARF, COPD ARF, Cardiogenic&#xD;
        acute pulmonary edema (APE).&#xD;
&#xD;
        Inclusion criteria for these 4 ARF subgroups are detailed below:&#xD;
&#xD;
        A. Inclusion Criteria for Non-Immunocompromised De Novo Hypoxemic ARF.&#xD;
&#xD;
        Patients must meet criteria 1, 2 and 3:&#xD;
&#xD;
          1. Hypoxemia evidenced by SpO2 &lt;90% or PaO2 &lt;60 mmHg in room air&#xD;
&#xD;
          2. Use of accessory muscles, paradoxical breathing, and/or thoracoabdominal asynchrony&#xD;
&#xD;
          3. RR&gt; 25 per minute&#xD;
&#xD;
        B. Inclusion Criteria for Immunocompromised De Novo Hypoxemic ARF.&#xD;
&#xD;
        Patients must meet criteria 1, 2, 3 and 4:&#xD;
&#xD;
          1. Immunosuppression diagnosis:&#xD;
&#xD;
             i. Use of Immunosuppressive drug or long-term [&gt;3 months] or high-dose [&gt;0.5&#xD;
             mg/kg/day] steroids ii. Solid organ transplantation iii. Extensive solid tumor or&#xD;
             solid tumor requiring chemotherapy in the last 5 years iv. Hematological malignancy&#xD;
             regardless of time since diagnosis and received treatments v. HIV infection vi.&#xD;
             Primary immunodefiency&#xD;
&#xD;
          2. Hypoxemia evidenced by SpO2 &lt;90% or PaO2 &lt;60 mmHg in room air&#xD;
&#xD;
          3. Use of accessory muscles, paradoxical breathing, and/or thoracoabdominal asynchrony&#xD;
&#xD;
          4. RR&gt; 25 per minute&#xD;
&#xD;
        C. Inclusion Criteria for COPD exacerbation:&#xD;
&#xD;
        Patients must meet criteria 1 or 2 and 3 and 4:&#xD;
&#xD;
          1. Previous Diagnosis of COPD based on GOLD guidelines&#xD;
&#xD;
          2. Strong clinical suspicion of COPD i. Smoker or ex-smoker or other CPOD related&#xD;
             exposure ii. Presence of chronic dyspnea on exertion or chronic productive cough iii.&#xD;
             Excluded other causes for the chronic symptoms (ex. pulmonary fibrosis, heart failure)&#xD;
&#xD;
          3. RR&gt; 25 per minute or use of accessory muscles, paradoxical breathing, and/or&#xD;
             thoracoabdominal asynchrony&#xD;
&#xD;
          4. ABG analysis with pH &lt; 7,35 , paCO2&gt; 45 mmHg&#xD;
&#xD;
        D. Inclusion Criteria for ARF secondary to Cardiogenic APE.&#xD;
&#xD;
        Patients must meet criteria numbers 1, 2 and 3:&#xD;
&#xD;
          1. Diagnosis of Cardiogenic Acute Pulmonary Edema (Nava, 2003):&#xD;
&#xD;
             i. Dyspnea of sudden onset ii. Widespread rales with or without third heart sound 1&#xD;
             iii. Absent history of pulmonary aspiration, infection or previous history of&#xD;
             pulmonary fibrosis iv. Pulmonary edema as the main clinical hypothesis v. Previous&#xD;
             heart failure clinical history or acute coronary syndrome vi. If chest X-ray is&#xD;
             already available at randomization, it must be suggestive of bilateral pulmonary edema&#xD;
&#xD;
          2. RR &gt; 25 per minute&#xD;
&#xD;
          3. SpO2 &lt; 95%&#xD;
&#xD;
        Exclusion Criteria for all subgroups of ARF&#xD;
&#xD;
          1. Indication of emergency ETI:&#xD;
&#xD;
               -  Prolonged respiratory pauses&#xD;
&#xD;
               -  Cardiorespiratory arrest&#xD;
&#xD;
               -  Glasgow ≤12&#xD;
&#xD;
               -  HR &lt; 50 bpm with decreased level of consciousness&#xD;
&#xD;
               -  pH &lt; 7.15 irrespective of the cause&#xD;
&#xD;
          2. Psychomotor agitation that prevents adequate medical / nursing care requiring heavy&#xD;
             sedation&#xD;
&#xD;
          3. Persistent hemodynamic instability with MAP &lt;65 mmHg, SBP &lt;90 mmHg after adequate&#xD;
             volume resuscitation or requiring norepinephrine&gt; 0.3 microg / kg / min or equivalent.&#xD;
&#xD;
          4. Contraindications to non-invasive ventilation: face deformities or traumas, recent&#xD;
             esophageal surgery, hypersecretion, vomiting with aspiration risk&#xD;
&#xD;
          5. Presence of pneumothorax or extensive pleural effusion&#xD;
&#xD;
          6. Severe arrhythmias at risk of hemodynamic instability&#xD;
&#xD;
          7. Thoracic trauma understood as the main cause of ARF&#xD;
&#xD;
          8. Asthma attack&#xD;
&#xD;
          9. Pregnancy&#xD;
&#xD;
         10. Cardiogenic Shock&#xD;
&#xD;
         11. Acute Coronary Syndromes with plans to undergo coronary angiography within 24 hs&#xD;
&#xD;
         12. ARF after orotracheal extubation (up to 72 hours after extubation)&#xD;
&#xD;
         13. Post-surgical ARF (surgery within 72 hours)&#xD;
&#xD;
         14. Hypercapnic ARF due to neuromuscular disease or chest deformities&#xD;
&#xD;
         15. Patients on exclusive palliative care&#xD;
&#xD;
         16. Do Not Intubate order (DNI)&#xD;
&#xD;
         17. Chronic pulmonary disease except COPD&#xD;
&#xD;
         18. Use of more than 6 hours of NIPPV before randomization if hypoxemic ARF in the&#xD;
             non-immunosuppressed, in the immunosuppressed hypoxemic, or if exacerbated COPD&#xD;
&#xD;
         19. Use of NIPPV before randomization in the cardiogenic acute pulmonary edema&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandre B Cavalcanti, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Research Institute - Hospital do Coracao, Sao Paulo, Brazil</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Israel Maia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Institute - Hospital do Coracao, Sao Paulo, Brazil</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leticia Kawano-Dourado, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Institute - Hospital do Coracao, Sao Paulo, Brazil</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laurent Brochard, MD</last_name>
    <role>Study Chair</role>
    <affiliation>St. Michael's Hospital (Toronto, Canada)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos R Carvalho, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Pulmonary Division University of Sao Paulo, Sao Paulo, Brazil</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Israel Maia, MD</last_name>
    <phone>+55 11 30536611</phone>
    <phone_ext>8209</phone_ext>
    <email>israels.maia@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leticia Kawano-Dourado, MD</last_name>
    <phone>+55 11 30536611</phone>
    <phone_ext>8209</phone_ext>
    <email>ldourado@hcor.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital do Coracao</name>
      <address>
        <city>São Paulo</city>
        <zip>05435000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcelo Romano, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Luzia Taniguchi, MSc</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 21, 2018</study_first_submitted>
  <study_first_submitted_qc>August 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2018</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>respiratory insufficiency</keyword>
  <keyword>respiratory failure</keyword>
  <keyword>non-invasive ventilation</keyword>
  <keyword>high flow nasal cannula</keyword>
  <keyword>nasal high flow</keyword>
  <keyword>trans-nasal insufflation</keyword>
  <keyword>NIV</keyword>
  <keyword>HFNC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Pulmonary Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

